• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » BMS announces global collaboration for immuno-oncology

BMS announces global collaboration for immuno-oncology

May 30, 2012
CenterWatch Staff

Global biopharmaceutical company Bristol-Myers Squibb has announced the formation of the International Immuno-Oncology Network (II-ON), a global collaboration between industry and academia that aims to further the scientific understanding of immuno-oncology (harnassing the body’s own immune system to fight cancer).

In addition to BMS, the II-ON is currently comprised of 10 leading cancer-research institutions, including:

  • Clinica Universidad Navarra, Pamplona, Spain
  • Dana-Farber Cancer Institute, Boston, Mass.
  • The Earle A. Chiles Research Institute (Providence Health & Services), Portland, Ore.
  • Institut Gustave Roussy, Villejuif, France
  • Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione G. Pascale," Naples, Italy
  • Johns Hopkins Kimmel Cancer Center, Baltimore, Md.
  • Memorial Sloan-Kettering Cancer Center, New York, N.Y.
  • The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, U.K.
  • The Netherlands Cancer Institute, Amsterdam, Netherlands
  • The University of Chicago, Chicago, Ill.

An objective of this collaborative forum is to facilitate the translation of scientific research findings into clinical trials and, eventually, clinical practice. It will also work to further advance innovation in drug discovery and development.

"The International Immuno-Oncology Network facilitates a public-private partnership that will leverage intellectual capabilities across a global network," said Elliott Sigal, M.D., Ph.D., executive vice president, chief scientific officer and president, R&D, Bristol-Myers Squibb. "The shared commitment of all those participating in this collaboration is to evolve our understanding of immuno-oncology towards our ultimate goal of improving patient outcomes."

The role of immuno-oncology in cancer research is growing and in 2011 the concept of "evading immune destruction" was added to the "Hallmarks of Cancer," a widely-referenced peer-reviewed article outlining traits that are believed to be the underlying principles of cancer.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing